In contrast to CD3(+)/CD31(-) cells, CD3(+)/CD31(+) cells aid in endothelial repair and revascularization. There are limited data regarding the functional differences between circulating CD3(+)/CD31(+) and CD3(+)/CD31(-) cells that may contribute to their divergent cardiovascular effects. The aim of the present study was to characterize functional differences between CD3(+)/CD31(+) and CD3(+)/CD31(-) cells. To address this aim, migratory capacity, proangiogenic cytokine release and apoptotic susceptibility of CD3(+)/CD31(+) and CD3(+)/CD31(-) cells were determined. Human CD3(+)/CD31(+) and CD3(+)/CD31(-)cells from peripheral blood were isolated using magnetic-activated cell sorting. CD3(+)/CD31(+) cells demonstrated significantly higher ( a...
BACKGROUND: Cell therapy for cardiovascular disease has been limited by low engraftment of administe...
Objective—Emerging evidence suggests that human blood contains bone marrow (BM)-derived endothelial ...
New FindingsWhat is the central question of the study?Are CD31+ angiogenic T (TANG) cells preferenti...
ObjectivesThis study aimed to determine if CD31 is a novel marker of a circulating angio-vasculogeni...
Objectives: This study aimed to determine if CD31 is a novel marker of a circulating angio-vasculoge...
Rationale: Bone marrow (BM) cells play an important role in physiological and therapeutic neovascula...
CD31(+) T cells, or so-called angiogenic T cells, have been shown to demonstrate vasculoprotective...
Within the phenotypically and functionally heterogeneous group of circulating progenitor cells (CPC)...
RATIONALE : Bone marrow (BM) cells play an important role in physiological and therapeutic neovascul...
Maintenance of vascular integrity during inflammation is a major challenge for the cooperation betwe...
AbstractCirculating endothelial progenitor cells (EPCs) provide revascularisation for cardiovascular...
Circulating endothelial progenitor cells (EPCs) provide revascularisation for cardiovascular disease...
ObjectiveIn cardiac cell therapy almost every cell type tested experimentally has yielded some benef...
AbstractBackgroundCell therapy for cardiovascular disease has been limited by low engraftment of adm...
CD31 is a 130,000 MW cell-surface glycoprotein expressed on endothelial cells, polymorphonuclear leu...
BACKGROUND: Cell therapy for cardiovascular disease has been limited by low engraftment of administe...
Objective—Emerging evidence suggests that human blood contains bone marrow (BM)-derived endothelial ...
New FindingsWhat is the central question of the study?Are CD31+ angiogenic T (TANG) cells preferenti...
ObjectivesThis study aimed to determine if CD31 is a novel marker of a circulating angio-vasculogeni...
Objectives: This study aimed to determine if CD31 is a novel marker of a circulating angio-vasculoge...
Rationale: Bone marrow (BM) cells play an important role in physiological and therapeutic neovascula...
CD31(+) T cells, or so-called angiogenic T cells, have been shown to demonstrate vasculoprotective...
Within the phenotypically and functionally heterogeneous group of circulating progenitor cells (CPC)...
RATIONALE : Bone marrow (BM) cells play an important role in physiological and therapeutic neovascul...
Maintenance of vascular integrity during inflammation is a major challenge for the cooperation betwe...
AbstractCirculating endothelial progenitor cells (EPCs) provide revascularisation for cardiovascular...
Circulating endothelial progenitor cells (EPCs) provide revascularisation for cardiovascular disease...
ObjectiveIn cardiac cell therapy almost every cell type tested experimentally has yielded some benef...
AbstractBackgroundCell therapy for cardiovascular disease has been limited by low engraftment of adm...
CD31 is a 130,000 MW cell-surface glycoprotein expressed on endothelial cells, polymorphonuclear leu...
BACKGROUND: Cell therapy for cardiovascular disease has been limited by low engraftment of administe...
Objective—Emerging evidence suggests that human blood contains bone marrow (BM)-derived endothelial ...
New FindingsWhat is the central question of the study?Are CD31+ angiogenic T (TANG) cells preferenti...